Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second-line docetaxel: A randomized trial.

At 12 months, that is, 6 months after the treatment with docetaxel +/‐ curcumin, the PFS rate was higher in the curcumin group (65.5%) than in the control group (41.4%); this difference was close to significance but failed to reach the usual level of significance ( p = 0.14). 3.4.4.

also in 2,130 other papers

The TTP and the PFS however seemed to be better in the experimental arm, but failed to reach significance, which leads us to confirm that adding curcumin to docetaxel did not potentiate the response.

also in 4,113 other papers